Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $44,437 | $61,030 | $86,560 | $102,489 |
| General and administrative | 12,817 | 14,768 | 24,391 | 28,305 |
| Total operating expenses | 57,254 | 75,798 | 110,951 | 130,794 |
| Loss from operations | (57,254) | (75,798) | (110,951) | (130,794) |
| Other income (expense): | ||||
| Interest income | 3,648 | 5,924 | 7,746 | 12,504 |
| Other expense, net | (98) | (181) | (160) | (266) |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s G&A?
- Cullinan Therapeutics, Inc. (CGEM) reported G&A of $12.82M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s G&A changed year-over-year?
- Cullinan Therapeutics, Inc.'s G&A decreased by 13.2% year-over-year, from $14.77M to $12.82M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s G&A has grown at a 16.8% compound annual growth rate (CAGR), from $29.15M to $54.25M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Cullinan Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude